All News
ACR 2018 - Day 3 Report
Highlights from Tuesday, day 3 of the ACR Annual meeting in Chicago, included the PEXIVAS Study, ACR Reproductive Health Draft Guidelines, and a Proof of concept study
Read Article2019 Rheumatology Year in Review
2019 was a year marked by major advances, hallmark research, and big news items affecting rheumatology. Herein you will find our top 10 list, formulated by what I think rheumatologists should know and what will likely change their standards and practice in 2020 and beyond.
Read ArticleACR-Arthritis Foundation Treatment Guidelines for Osteoarthritis
Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee.
Read ArticleTaltz Shines in Non-Radiographic Axial Spondyloarthritis
Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA).
Read ArticleDr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Claims data from RA patients (n = 12,182), shows that screening for hyperlipidemia was suboptimal (compared to Diabetes pts), Those seeing a PCP and Rheum were 36% more likely to be screened. https://t.co/j661loTDGk
Links:
From the 9/11 World Trade Center registry, 118 persons found w/ a CTD (RA=71, Sjӧgrens 22, SLE 20, myositis 9,MCTD 7, PSS 4. Responders w/ intense dust cloud exposure had 2 fold CTD risk & Community members w/ PTSD had 3‐fold risk. https://t.co/07GhloezNA
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)